Pre- and postoperative adjuvant therapy for locally advanced rectal cancer.

Laura P. McGartland*, Mary Frances Mulcahy, Al B Benson III

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

4 Scopus citations


The conventional therapy for locally advanced rectal cancer involves surgery and adjuvant therapy. The standard adjuvant therapy is combined modality treatment, including 5-fluorouracil chemotherapy and radiation. The standard of care in terms of timing of adjuvant therapy, whether pre- or postoperative, continues to evolve, and potential advantages and disadvantages exist for both neoadjuvant and adjuvant combined modality therapy. Newer modalities of assessment, such as endoscopic ultrasound, have had an impact on more accurate staging of locally advanced rectal cancer, thus impacting the choice of therapy. Continued emphasis on improving survival, decreasing local recurrence, and minimizing treatment toxicity to improve quality of life are the goals of ongoing research in the field of rectal cancer.

Original languageEnglish (US)
Pages (from-to)806-814
Number of pages9
JournalClinical advances in hematology & oncology : H&O
Issue number12
StatePublished - Jan 1 2004

ASJC Scopus subject areas

  • Hematology
  • Oncology


Dive into the research topics of 'Pre- and postoperative adjuvant therapy for locally advanced rectal cancer.'. Together they form a unique fingerprint.

Cite this